Current standard of care for inoperable stage III NSCLC [Video]

Ticiana Leal, MD, Winship Cancer Institute, Atlanta, GA, explains the current standard of care for inoperable stage III non-small cell lung cancer (NSCLC). The first line treatment is combined chemotherapy and radiation, followed by immunotherapy with durvalumab, as outlined in the PACIFIC study (NCT02125461), which demonstrated improved progression-free survival (PFS) and overall survival (OS). This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.